SEC Comment Letter for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883) (BCLI) — Jun 19, 2018
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883)
Date: June 19, 2018 · CIK: 0001137883 · Accession: 0000000000-18-018857
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-225517
Letter
June 19, 2018 Chaim Lebovits President and Chief Executive Officer Brainstorm Cell Therapeutics Inc. 1745 Broadway, 17th Floor New York, NY 10019 Re:Brainstorm Cell Therapeutics Inc. Registration Statement on Form S-3 Filed June 8, 2018 File No. 333-225517 Dear Mr. Lebovits: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at 202-551-5019 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Thomas B. Rosedale, Esq.
Show Raw Text
June 19, 2018
Chaim Lebovits
President and Chief Executive Officer
Brainstorm Cell Therapeutics Inc.
1745 Broadway, 17th Floor
New York, NY 10019
Re:Brainstorm Cell Therapeutics Inc.
Registration Statement on Form S-3
Filed June 8, 2018
File No. 333-225517
Dear Mr. Lebovits:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at 202-551-5019 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Thomas B. Rosedale, Esq.